Cite
High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells.
MLA
Zeng, Zhihong, et al. “High-Throughput Proteomic Profiling Reveals Mechanisms of Action of AMG925, a Dual FLT3-CDK4/6 Kinase Inhibitor Targeting AML and AML Stem/Progenitor Cells.” Annals of Hematology, vol. 100, no. 6, June 2021, pp. 1485–96. EBSCOhost, https://doi.org/10.1007/s00277-021-04493-0.
APA
Zeng, Z., Ly, C., Daver, N., Cortes, J., Kantarjian, H. M., Andreeff, M., & Konopleva, M. (2021). High-throughput proteomic profiling reveals mechanisms of action of AMG925, a dual FLT3-CDK4/6 kinase inhibitor targeting AML and AML stem/progenitor cells. Annals of Hematology, 100(6), 1485–1496. https://doi.org/10.1007/s00277-021-04493-0
Chicago
Zeng, Zhihong, Charlie Ly, Naval Daver, Jorge Cortes, Hagop M. Kantarjian, Michael Andreeff, and Marina Konopleva. 2021. “High-Throughput Proteomic Profiling Reveals Mechanisms of Action of AMG925, a Dual FLT3-CDK4/6 Kinase Inhibitor Targeting AML and AML Stem/Progenitor Cells.” Annals of Hematology 100 (6): 1485–96. doi:10.1007/s00277-021-04493-0.